PTC Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PTCT and other ETFs, options, and stocks.

About PTCT

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ. 

CEO
Matthew B. Klein
CEOMatthew B. Klein
Employees
991
Employees991
Headquarters
Warren, New Jersey
HeadquartersWarren, New Jersey
Founded
1998
Founded1998
Employees
991
Employees991

PTCT Key Statistics

Market cap
5.25B
Market cap5.25B
Price-Earnings ratio
8.44
Price-Earnings ratio8.44
Dividend yield
Dividend yield
Average volume
1.36M
Average volume1.36M
High today
$65.65
High today$65.65
Low today
$62.13
Low today$62.13
Open price
$64.70
Open price$64.70
Volume
1.02M
Volume1.02M
52 Week high
$87.50
52 Week high$87.50
52 Week low
$35.95
52 Week low$35.95

Stock Snapshot

The current PTC Therapeutics(PTCT) stock price is $63.36, with a market capitalization of 5.25B. The stock trades at a price-to-earnings (P/E) ratio of 8.44.

As of 2026-03-12, PTC Therapeutics(PTCT) stock has fluctuated between $62.13 and $65.65. The current price stands at $63.36, placing the stock +2.0% above today's low and -3.5% off the high.

PTC Therapeutics(PTCT) shares are trading with a volume of 1.02M, against a daily average of 1.36M.

In the last year, PTC Therapeutics(PTCT) shares hit a 52-week high of $87.50 and a 52-week low of $35.95.

In the last year, PTC Therapeutics(PTCT) shares hit a 52-week high of $87.50 and a 52-week low of $35.95.

PTCT News

Simply Wall St 19h
FDA Shift Reframes PTC Therapeutics Regulatory Risks And Reward Profile

Biotech sentiment has improved following an FDA leadership change that investors view as easing regulatory hurdles for cell and gene therapies. PTC Therapeutic...

FDA Shift Reframes PTC Therapeutics Regulatory Risks And Reward Profile

Analyst ratings

64%

of 14 ratings
Buy
64.3%
Hold
28.6%
Sell
7.1%

People also own

Based on the portfolios of people who own PTCT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.